Jonathan C. Trent, MD

home / authors / jonathan-c-trent-md

Articles

Jonathan C. Trent, MD, PhD, of Sylvester Comprehensive Cancer Center

Dr. Trent on the Need for Novel Combination Strategies in Metastatic GIST

Jonathan C. Trent, MD
February 24th 2021

Jonathan C. Trent, MD, PhD, discusses the need to develop novel combination strategies for the treatment of patients with metastatic gastrointestinal stromal tumors.

Read More

Jonathan C. Trent, MD, PhD

Dr. Trent on the Role of Adjuvant Imatinib in GIST

Jonathan C. Trent, MD
January 6th 2021

Jonathan C. Trent, MD, PhD, discusses the role of adjuvant imatinib in gastrointestinal stromal tumors.

Read More

Dr. Trent on the Role of ctDNA in Soft Tissue Sarcoma

Dr. Trent on the Role of ctDNA in Soft Tissue Sarcoma

Jonathan C. Trent, MD
August 7th 2020

Jonathan C. Trent, MD, PhD, discusses the role of circulating tumor DNA in soft tissue sarcoma. 

Read More

Dr. Trent on Sequencing Trabectedin for Patients With Soft Tissue Sarcoma

Dr. Trent on Sequencing Trabectedin for Patients With Soft Tissue Sarcoma

Jonathan C. Trent, MD
December 2nd 2015

Jonathan C. Trent, MD, associate director for Clinical Research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses sequencing trabectedin (Yondelis) for patients with soft tissue sarcoma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need